May 28, 2025
Mitsubishi Tanabe Pharma America Announces U.S. FDA Acceptance of New Drug Application Resubmission for Investigational ND0612 for the Treatment of Motor Fluctuations in Parkinson's Disease
Mar 25, 2025
Mitsubishi Tanabe Pharma America Announces Publication of Preclinical Research on the Role of Edaravone in Mitigating TDP-43 Mislocalization in ALS
Dec 17, 2024
Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS
Dec 03, 2024
Mitsubishi Tanabe Pharma America to Present New ALS Research at MNDA's 35th International Symposium on ALS/MND
Oct 15, 2024
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2024 AANEM Annual Meeting
Oct 06, 2024
Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Data at the 2024 National Association of Specialty Pharmacy Annual Meeting
Sep 27, 2024
Mitsubishi Tanabe Pharma America to Highlight Data on Investigational ND0612 at the 2024 International Congress of Parkinson's Disease and Movement Disorders
Sep 17, 2024
Mitsubishi Tanabe Pharma America to Showcase RADICAVA ORS® (edaravone) Presentations at 2024 Neuromuscular Study Group Annual Meeting
Jul 09, 2024
Mitsubishi Tanabe Pharma America to Feature RADICAVA ORS® (edaravone) Real-World Data at 2024 ALS Nexus Conference
Jun 28, 2024
Mitsubishi Tanabe Pharma America to Present Latest Parkinson's Disease Research at the 10th Congress of the European Academy of Neurology
Jun 17, 2024
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA® (edaravone) for People Living with ALS at the European Network to Cure ALS (ENCALS) Meeting 2024
May 16, 2024
Mitsubishi Tanabe Pharma America Announces Presentations at XXIX World Congress on Parkinson's Disease and Related Disorders
May 03, 2024
Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Real-World Data at the Professional Society for Health Economics and Outcomes Research 2024 Annual Meeting
Apr 29, 2024
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
Apr 15, 2024
Mitsubishi Tanabe Pharma America to Present Healthcare Resource Utilization Data in RADICAVA ORS® (edaravone)-Treated ALS Patients at AMCP 2024
Apr 08, 2024
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
Mar 18, 2024
Mitsubishi Tanabe Pharma America Announces Publication of Positive Results from Phase 3 BouNDless Trial of Investigational ND0612 in People with Parkinson's Disease Experiencing Motor Fluctuations
Mar 04, 2024
Mitsubishi Tanabe Pharma America Announces Presentations in Parkinson's Disease at 2024 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)
Mar 01, 2024
Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference